Duchenne muscular dystrophy (DMD) is the most frequent muscle disease in children. The birth prevalence of DMD is around 1 in 3500 live born males. The milder Becker muscular dystrophy (BMD) has a lower birth prevalence of around 1 in 18 500 live born males.' DMD and BMD are allelic X linked recessive diseases caused by mutations in the dystrophin gene in the middle of the short arm of the X chromosome (Xp2 1).
Female relatives of DMD and BMD patients, including mothers, sisters, nieces, aunts, and cousins, often request genetic counselling and genetic testing as these diseases are incurable, severely disabling, and cause early death. In the genetic analysis of the family, the first question to be answered is how reliable the diagnosis is in the index case. The A woman with one affected son and no family history of muscular dystrophy is either: (1) a full carrier; (2) a somatic mosaic coinciding with a partially (germline mosaicism) or totally affected germline; (3) a germline mosaic; (4) not a carrier, the ovum from which her son arose contained a new mutation; (5) not a carrier, her diseased son is a somatic mosaic. Depending on the proportion of muscle cells that contain the mutation, a wide clinical spectrum can be expected.
Sisters of a boy apparently affected by a new mutation are at risk of being a carrier because the mother can be a germline mosaic. Subsequent brothers have the same risk of being affected by the same mutation. This risk lies in the order of 5-10%.20 24 We wish to stress that the same risk applies to the sisters of a woman who is apparently a carrier owing to a new mutation.
A woman with more than one affected son and no family history of muscular dystrophy can be: (1) a full carrier; (2) a somatic mosaic including her germline; (3) a germline mosaic.
If a woman has an affected son and also has affected relatives in the maternal line, she is regarded as a definite carrier. A woman with one or more affected brothers but no affected offspring is a possible carrier.
A woman can be a carrier because: (1) she inherited the mutation from her mother who is a carrier; (2) her mother or her father is a somatic mosaic including the germline; (3) her mother or her father is a germline mosaic; (4) the ovum or sperm from which she arose contained a new mutation; (5) Figure 3 The cDNA blot hybridised with probe 4 shows a deletion of exon 53 (del) in the DMD patient (5) and results in a junction fragment (J). Halfintensity of the relevant band in the mother (2) Southern blotting Southern blotting is more labour intensive than PCR, usually takes several days, and requires a minimum of 5 ,ug genomic DNA. Southern blot analysis using dystrophin cDNA probes has been described by Darras and Francke, 48 Bakker et al,4 and Mao and Cremer. 49 In patients. Deletions are recognised as absent bands or band shifts (junction bands or J bands) on the autoradiogram (figs 3 and 4). J bands are found in less than 5% of patients. Duplications appear as a double band intensity in comparison to the normal situation or as band shifts. Genomic probes (cosmids) can also be used to detect J bands, which are found in 81% of precisely mapped deletions. 50 The technically more demanding pulsed field gel electrophoresis (PFGE) or field inversion electrophoresis (FIGE)5' are methods to separate long DNA fragments produced by rare cutting enzymes and usually show J bands in deletions larger than 20 kb. Alternatively, a newly developed Southern blotting based method uses rare cutting restriction enzymes and electrophoresis of single stranded DNA and detects J bands in almost 80% of patients with deletions and duplications. 52 In carriers. Deletions or duplications which produce a J band make carrier detection easy Single strand conformation polymorphism (SSCP) SSCP has the potential to detect all small mutations. A mutation in the single DNA strand causes altered folding and thus altered migration during electrophoresis. In practice, 35-100% of known mutations can be detected as an aberrant band pattern by SSCP and its modifications.66 69 Application of various different electrophoretic conditions increases the chance of finding an aberrant band caused by the mutation (fig 5) . SSCP of exons of the deletion prone regions leads to the detection of pathogenic mutations in about 10% of cases.32 70 Carrier detection by differences in band intensities should preferably be confirmed using informative polymorphisms in the region corresponding to the deletion. This means that DNA of the parents of the carrier should also be available. Short tandem repeat (STR) In DMD or BMD diagnosed with certainty, SSCP, HDA, PTT, or another test for mutation scanning should be tried to screen the dystrophin gene for a mutation whenever possible. When an aberrant band is found, that band must be amplified and sequenced for a pathogenic mutation. Carrier detection will then also be possible by sequencing this region. When the mutation produces or abolishes a restriction site, restriction analysis can be used as a ready confirmation of carrier status.
In families where the mutation cannot be detected, carrier risks have to be based on the pedigree, serum CK activities in close female relatives, and linkage data using flanking and intragenic markers. In these cases automated calculation programs can be helpful. However, possible recombinations remain a drawback in linkage analysis. The very high intragenic recombination of 12% across the dystrophin gene43 88 embryos at risk for a deletion of exons 3-18 and three were found to be normal and were replaced. A singleton pregnancy was the eventual result.
Discussion
Although the possibilities for detecting microlesions in the dystrophin gene are increasing, still for the near future in about 30% of families mutation detection will not be in the standard package of most diagnostic laboratories. Fortunately, linkage analysis and determination of serum CK activities in female relatives mostly enable a fairly accurate determination of carrier risks in these families. This may even be possible when no DNA from the patient is available. However, families with patients who have already died might pose serious problems in assigning carriers risks, although the PTT and other approaches might directly detect female carriers. Therefore, every physician involved with muscular dystrophy patients should obtain and store cells from DMD and BMD patients for DNA and RNA extraction or for establishing a cell line or both.
In practice, DGGE may detect more mutations than SSCP. Therefore, further development of DGGE will be worthwhile. In a two dimensional DNA electrophoresis method, DGGE preceded by extensive PCR multiplexing has recently been proven to be very effective in detecting mutations in the 200 kb sized RB 1 gene with its 27 exons."12 The ideal setting for the future is a quick reliable mutation scanning system for the whole dystrophin gene. Two dimensional DNA electrophoresis" 2 "II might have this potential and needs to be evaluated further.
At present prenatal diagnosis by chorion villus sampling will be the only realistic option for many DMD and BMD carriers who want to have children of their own. PID needs to be optimalised in order to become a more acceptable option for many parents. In polar body biopsy the at risk haplotype or mutation in the polar body implies presence of the normal allele in the primary oocyte, but this method has not been used in diagnosis of DMD or BMD.
As the majority of DMD and BMD cases cannot be prevented, hopefully gene therGpy will provide young DMD and BMD patients with a way of stopping disease progression. However 
